Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded New York and Oregon locations in the Locations section and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; there are no changes to the study details, eligibility criteria, outcomes, or other user-facing content.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; no study details or page content were modified.SummaryDifference0.1%

- Check53 days agoChange DetectedThe government funding status notice banner has been removed from the page. This change does not affect the study details or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check67 days agoChange DetectedNo substantive changes detected on the Study Details page for NCT03650894. The information and layout appear unchanged from the prior state.SummaryDifference0.5%

- Check95 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the old v3.1.0 revision.SummaryDifference3%

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.